Krystal Biotech, Inc. disclosed a single-patient observation from a discontinued clinical study for KB801, an investigational gene therapy for neurotrophic keratitis, following a response to a USPTO Office Action. The patient experienced complete closure of a persistent corneal epithelial defect. Krystal Biotech, Inc. is a biotechnology company developing gene therapies.
